Poly (I:C) downregulates platelet production and function through type I interferon

Thrombosis and Haemostasis

Volumn 114, Issue 5, 2015, Pages 982-993

  Rivadeneyra, Leonardo ^a   Pozner, Roberto Gabriel ^a   Meiss, Roberto ^a   Fondevila, Carlos ^b   Gómez, Ricardo Martin ^c   Schattner, Mirta ^a  

^a ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^b Interventional Cardiology Department   (Argentina)

^c Inst de Biotecnología Y Biología Molecular IBBM   (Argentina)

Author keywords

Interferon; Platelets; Poly (I:C); Thrombocytopaenia; Virus

Indexed keywords

BETA INTERFERON; DOUBLE STRANDED RNA; INTERFERON; PADGEM PROTEIN; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN AGGREGATE; RANTES; TOLL LIKE RECEPTOR 3; VON WILLEBRAND FACTOR; ALPHA BETA INTERFERON RECEPTOR; FIBRINOGEN; IFNAR1 PROTEIN, MOUSE;

ANIMAL TISSUE; ARTICLE; BLEEDING; BLEEDING TIME; BLOOD ANALYSIS; BLOOD CLOT RETRACTION; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENETIC ANALYSIS; HEMOSTASIS; MEGAKARYOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; THROMBOCYTE ADHESION; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; THROMBOCYTE VOLUME; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; ANIMAL; C57BL MOUSE; CELL DIFFERENTIATION; DRUG EFFECTS; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY; THROMBOCYTE; THROMBOCYTE ACTIVATION;

ANIMALS; BLEEDING TIME; BLOOD PLATELETS; CELL DIFFERENTIATION; CHEMOKINE CCL5; FEMALE; FIBRINOGEN; INTERFERON-BETA; MEGAKARYOCYTES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; P-SELECTIN; PLATELET ACTIVATION; POLY I-C; RECEPTOR, INTERFERON ALPHA-BETA; THROMBOCYTOPENIA; THROMBOPOIESIS;

EID: 84946615461     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-11-0951     Document Type: Article

References (35)

1. Flaujac C, Boukour S, Cramer-Borde E. Platelets and viruses: an ambivalent relationship. Cell Mol Life Sci 2010; 67: 545–556.
2. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987–995.
3. Theofilopoulos AN, Baccala R, Beutler B, et al. Type I interferons ([alpha]/[beta]) in immunity and autoimmunity. Annu Rev Immunol 2005; 23: 307–336.
4. Le Bon A, Tough DF. Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 2002; 14: 432–436.
5. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol 2014; 14: 36–49.
6. Novick D, Cohen B, Rubinstein M. The human interferon alpha/beta receptor: characterization and molecular cloning. Cell 1994; 77: 391–400.
7. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34: 637–650.
8. Iannacone M, Sitia G, Isogawa M, et al. Platelets prevent IFN-alpha/beta-induced lethal hemorrhage promoting CTL-dependent clearance of lymphocytic choriomeningitis virus. Proc Natl Acad Sci USA 2008; 105: 629–634.
9. Alexopoulou L, Holt AC, Medzhitov R, et al. Recognition of double-stranded RNA and activation of NF-[kappa]B by Toll-like receptor 3. Nature 2001; 413: 732–738.
10. Pozner RG, Ure AE, Jaquenod de Giusti C, et al. Junin virus infection of human hematopoietic progenitors impairs in vitro proplatelet formation and platelet release via a bystander effect involving type I IFN signaling. PLoS Pathog 2010; 6: e1000847.
11. Wang Q, Miyakawa Y, Fox N, et al. Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood 2000; 96: 2093–2099.
12. Yamane A, Nakamura T, Suzuki H, et al. Interferon-alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes. Blood 2008; 112: 542–550.
13. Negrotto S, De Giusti CJ, Lapponi MJ, et al. Expression and functionality of type I interferon receptor in the megakaryocytic lineage. J Thromb Haemost 2011; 9: 2477–2485.
14. Wang BX, Rahbar R, Fish EN. Interferon: current status and future prospects in cancer therapy. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Res 2011; 31: 545–552.
15. Aranda F, Vacchelli E, Obrist F, et al. Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunol 2014; 3: e29179.
16. Martins KA, Bavari S, Salazar AM. Vaccine adjuvant uses of poly-IC and derivatives. Expert Rev Vacc 2015; 14: 447–459.
17. Malaver E, Romaniuk MA, D’Atri LP, et al. NF-kappaB inhibitors impair platelet activation responses. J Thromb Haemost 2009; 7: 1333–1343.
18. Rivadeneyra L, Carestia A, Etulain J, et al. Regulation of platelet responses triggered by Toll-like receptor 2 and 4 ligands is another non-genomic role of nuclear factor-kappaB. Thromb Res 2014; 133: 235–243.
19. Christopher MJ, Liu F, Hilton MJ, et al. Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization. Blood 2009; 114: 1331–1339.
20. Rondina MT, Garraud O. Emerging evidence for platelets as immune and inflammatory effector cells. Front Immunol 2014; 5: 653.
21. Tucker K, Sage T, Gibbins J. Clot Retraction. In: Platelets and Megakaryocytes. Springer New York; 2012; pp. 101–107.
22. Chu SG, Becker RC, Berger PB, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 2010; 8: 148–156.
23. Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinol 1996; 7: 157–161.
24. Noris P, Klersy C, Zecca M, et al. Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. J Thromb Haemost 2009; 7: 2131–2136.
25. Schmitt A, Guichard J, Masse JM, et al. Of mice and men: comparison of the ultrastructure of megakaryocytes and platelets. Exp Hematol 2001; 29: 1295–1302.
26. Harker LA, Marzec UM, Kelly AB, et al. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor. Blood 1997; 89: 155–165.
27. Sola-Visner MC, Christensen RD, Hutson AD, et al. Megakaryocyte size and concentration in the bone marrow of thrombocytopenic and nonthrombocytopenic neonates. Pediatr Res 2007; 61: 479–484.
28. Avecilla ST, Hattori K, Heissig B, et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med 2004; 10: 64–71.
29. Niswander LM, Fegan KH, Kingsley PD, et al. SDF-1 dynamically mediates megakaryocyte niche occupancy and thrombopoiesis at steady state and following radiation injury. Blood 2014; 124: 277–286.
30. Zimmer S, Steinmetz M, Asdonk T, et al. Activation of endothelial toll-like receptor 3 impairs endothelial function. Circulation Res 2011; 108: 1358–1366.
31. D’Atri LP, Etulain J, Rivadeneyra L, et al. Expression and functionality of Tolllike receptor 3 in the megakaryocytic lineage. J Thromb Haemost 2015; Epub ahead of print.
32. Reimer T, Brcic M, Schweizer M, et al. poly(I:C) and LPS induce distinct IRF3 and NF-kappaB signaling during type-I IFN and TNF responses in human macrophages. J Leukocyte Biol 2008; 83: 1249–1257.
33. Ernstoff MS, Kirkwood JM. Changes in the bone marrow of cancer patients treated with recombinant interferon alpha-2. Am J Med 1984; 76: 593–596.
34. Kreft A, Nolde C, Busche G, et al. Polycythaemia vera: bone marrow histopathology under treatment with interferon, hydroxyurea and busulphan. Eur J Haematol 2000; 64: 32–41.
35. Sata M, Yano Y, Yoshiyama Y, et al. Mechanisms of thrombocytopenia induced by interferon therapy for chronic hepatitis B. J Gastroenterol 1997; 32: 206–210.